Latest total liabilities for ADPT: $490M.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
Adaptive Biotechnologies (ADPT) currently reports a total liabilities of $490M as of June 2026. That compares with $320M in the prior-year period — up 54.5% year over year. Use the charts on this page to explore Adaptive Biotechnologies's total liabilities history and peer comparisons.
Adaptive Biotechnologies's total liabilities increased from $320M to $490M — a 54.5% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
Adaptive Biotechnologies reported $490M in total liabilities as of June 2026. That compares with $320M in the prior-year period — up 54.5% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.
Start with the current total liabilities of $490M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Adaptive Biotechnologies, and consider following ADPT for alerts when major investors trade the stock.
Adaptive Biotechnologies is classified in the Healthcare sector. On total liabilities, it currently shows $490M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ADPT with unrelated industries.